meta
|
evidence
oncology
Living systematic review and meta-analysis
metastatic-recurrent HNSCC (mHNSCC)
mHNSCC - (neo)adjuvant (NA)
mHNSCC - 1st line (L1)
mHNSCC - L1 - all population
2
mHNSCC - L1 - PDL1 positive
4
mHNSCC - 2nd line (L2)
mHNSCC - L2 - all population
4
mHNSCC - L2 - PDL1 negative
2
mHNSCC - L2 - PDL1 positive
1
hepatocell cancer (HCC)
1
immune chekpoint inhibitors
Immune checkpoint association
durvalumab plus tremelimumab
versus all
vs immune chekpoint inhibitors
vs anti-CTLA-4
vs tremelimumab
vs anti-PD-(L)1
vs durvalumab based treatment
vs durvalumab alone
study list
mapping
overview
meta-analysis
forest plot
NMA
excluded
graph
EGM
comparisons
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
durvalumab plus tremelimumab
title
durvalumab alone
title
tremelimumab
title
CONDOR (DT vs D ; PDL1 TC<25%), 2019 NCT02319044 mHNSCC - L2 - PDL1 negative 133/67
CONDOR (DT vs T ; PDL1 TC<25%), 2019 NCT02319044 mHNSCC - L2 - PDL1 negative 133/67
Pathology:
mHNSCC - L2 - PDL1 negative;
mHNSCC - L2 - PDL1 negative
CONDOR (DT vs D ; PDL1 TC<25%), 2019
CONDOR (DT vs T ; PDL1 TC<25%), 2019
durvalumab plus tremelimumab
2
T1
T1
durvalumab alone
0
T0
tremelimumab
0
T0